# Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Study · id `cardio:ct-nct05691244` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05691244](<https://clinicaltrials.gov/study/NCT05691244>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05691244

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 514 participants.

## Technical summary

Registry record NCT05691244. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-24 (actual); primary completion 2027-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 514 participants (planned count; ClinicalTrials.gov record NCT05691244, source copy `cardio:ctgov-nct05691244-2026-11-13`, retrieved 2026-11-18)
- Started: 2025-07-24 (actual) (ClinicalTrials.gov record NCT05691244, source copy `cardio:ctgov-nct05691244-2026-11-13`, retrieved 2026-11-18)
- Primary completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT05691244, source copy `cardio:ctgov-nct05691244-2026-11-13`, retrieved 2026-11-18)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT05691244, source copy `cardio:ctgov-nct05691244-2026-11-13`, retrieved 2026-11-18)
- Countries: United States; Australia; Germany; Spain; United Kingdom (ClinicalTrials.gov record NCT05691244, source copy `cardio:ctgov-nct05691244-2026-11-13`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05691244-2026-11-13`, retrieved 2026-11-18)

## The registry's words

- Brief title: Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
- Acronym: RESPECT-ETB
- Condition: Acute Ischemic Stroke
- Condition: Cerebral Stroke
- Intervention (Drug): Drug: Normal Saline
- Intervention (Drug): Sovateltide
- Lead sponsor: Pharmazz, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Pharmazz, Inc. (`cardio:org-pharmazz-inc`)

## Provenance

Content hash: 88bee31a935a8b448e9ae1a8c9aaf36107bc36e2b2a0e131ee8954534f517407
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
